Alterations in Choline Metabolism in Non-Obese Individuals with Insulin Resistance and Type 2 Diabetes Mellitus

被引:1
|
作者
Al-Sulaiti, Haya [1 ,2 ]
Anwardeen, Najeha [2 ]
Bashraheel, Sara S. [3 ]
Naja, Khaled [2 ]
Elrayess, Mohamed A. [2 ,3 ]
机构
[1] Qatar Univ, Coll Hlth Sci, Dept Biomed Sci, QU Hlth, POB 2713, Doha, Qatar
[2] Qatar Univ, Biomed Res Ctr, POB 2713, Doha, Qatar
[3] Qatar Univ, Coll Med, QU Hlth, POB 2713, Doha, Qatar
关键词
phospholipid metabolites; choline phosphate; glycerophosphoethanolamine; choline; glycerophosphorylcholine (GPC); trimethylamine N-oxide choline; metabolomics; non-obese; insulin resistance; type 2 diabetes mellitus; TRIMETHYLAMINE-N-OXIDE; TMAO; PHOSPHATIDYLETHANOLAMINE;
D O I
10.3390/metabo14080457
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The prevalence of non-obese individuals with insulin resistance (IR) and type 2 diabetes (T2D) is increasing worldwide. This study investigates the metabolic signature of phospholipid-associated metabolites in non-obese individuals with IR and T2D, aiming to identify potential biomarkers for these metabolic disorders. The study cohort included non-obese individuals from the Qatar Biobank categorized into three groups: insulin sensitive, insulin resistant, and patients with T2D. Each group comprised 236 participants, totaling 708 individuals. Metabolomic profiling was conducted using high-resolution mass spectrometry, and statistical analyses were performed to identify metabolites associated with the progression from IS to IR and T2D. The study observed significant alterations in specific phospholipid metabolites across the IS, IR, and T2D groups. Choline phosphate, glycerophosphoethanolamine, choline, glycerophosphorylcholine (GPC), and trimethylamine N-oxide showed significant changes correlated with disease progression. A distinct metabolic signature in non-obese individuals with IR and T2D was characterized by shifts in choline metabolism, including decreased levels of choline and trimethylamine N-oxide and increased levels of phosphatidylcholines, phosphatidylethanolamines, and their degradation products. These findings suggest that alterations in choline metabolism may play a critical role in the development of glucose intolerance and insulin resistance. Targeting choline metabolism could offer potential therapeutic strategies for treating T2D. Further research is needed to validate these biomarkers and understand their functional significance in the pathogenesis of IR and T2D in non-obese populations.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] The Pathophysiology of Type 2 Diabetes Mellitus in Non-obese Individuals: An Overview of the Current Understanding
    Olaogun, Idowu
    Farag, Mina
    Hamid, Pousettef
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (04)
  • [2] Cholesterol metabolism in obese and non-obese subjects with type 2 diabetes
    Simonen, PP
    Gylling, HK
    Miettinen, TA
    CIRCULATION, 2000, 102 (18) : 283 - 283
  • [3] Insulin resistance and sensitivity in context of dyslipidemia in non-obese type 2 diabetes patients
    Tiwari, D.
    Tripathi, P.
    Kadam, N.
    Vyawahare, A.
    Sharma, B.
    Kathrikolly, T.
    Ganla, M.
    Saboo, B.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 209
  • [4] Reversible peripheral insulin resistance in non-obese patients with non-insulin-dependent diabetes mellitus
    Katsuki, A
    Sumida, Y
    Murashima, S
    Furuta, M
    Ito, K
    Sasaki, R
    Tsuchihashi, K
    Hori, Y
    Nakatani, K
    Yano, Y
    Gabazza, EC
    Adachi, Y
    MEDICAL SCIENCE RESEARCH, 1999, 27 (08): : 517 - 518
  • [5] The association between impaired proinsulin processing and type 2 diabetes mellitus in non-obese Japanese individuals
    Katsuta, Hidenori
    Ozawa, Sachihiko
    Suzuki, Kiyoshi
    Takahashi, Kazuto
    Tanaka, Toshiaki
    Sumitani, Yoshikazu
    Nishida, Susumu
    Kondo, Takuma
    Hosaka, Toshio
    Inukai, Kouichi
    Ishida, Hitoshi
    ENDOCRINE JOURNAL, 2015, 62 (06) : 485 - 492
  • [6] Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus
    Christophe Bardin
    Estelle Nobecourt
    Etienne Larger
    François Chast
    Jean-Marc Treluyer
    Saik Urien
    European Journal of Clinical Pharmacology, 2012, 68 : 961 - 968
  • [7] Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus
    Bardin, Christophe
    Nobecourt, Estelle
    Larger, Etienne
    Chast, Francois
    Treluyer, Jean-Marc
    Urien, Saik
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (06) : 961 - 968
  • [8] Distinct cardiac energy metabolism and oxidative stress adaptations between obese and non-obese type 2 diabetes mellitus
    Li, Xinghui
    Wu, Yandi
    Zhao, Jingjing
    Wang, Haiping
    Tan, Jing
    Yang, Ming
    Li, Yuanlong
    Deng, Shijie
    Gao, Saifei
    Li, Hui
    Yang, Zhenyu
    Yang, Fengmin
    Ma, Jianxing
    Cheng, Jianding
    Cai, Weibin
    THERANOSTICS, 2020, 10 (06): : 2675 - 2695
  • [9] COMPARISON OF INSULIN-SECRETION AND INVIVO INSULIN ACTION IN NON-OBESE AND MODERATELY OBESE INDIVIDUALS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS
    REAVEN, GM
    DOBERNE, L
    GREENFIELD, MS
    DIABETES, 1982, 31 (05) : 382 - 384
  • [10] Investigating for Insulin Resistance and Type 2 Diabetes Mellitus in Obese Children
    Simsek, Enver
    Karabay, Meltem
    Aras, Sukru
    Kocabay, Kenan
    TURKISH JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2005, 9 (01) : 17 - 22